Your DNA Is Now a Key Clue in Predicting Heart Disease Risk

MENLO PARK, Calif. – March 20, 2026 – The playbook for preventing heart disease, the leading cause of death worldwide, is being rewritten. In a landmark update, the nation’s top cardiology organizations have officially recognized that a person's genetic makeup is a critical factor in assessing their future risk, a move that promises to shift cardiovascular care toward a more personalized, predictive, and preventive model.

This month, the American College of Cardiology (ACC) and the American Heart Association (AHA) released their 2026 dyslipidemia guidelines, which for the first time name high polygenic risk as an “atherosclerotic cardiovascular disease (ASCVD) risk enhancer.” This designation places a person’s inherited genetic susceptibility on par with established risk factors like a family history of premature heart attacks or elevated inflammatory markers.

The change signals a major validation for the field of genomic medicine and for companies like MyOme, a Menlo Park-based firm specializing in whole-genome analysis. Coinciding with the guideline update, MyOme announced new research published in the American Journal of Preventive Cardiology demonstrating that its platform, which integrates genetic data with traditional clinical factors, provides more precise and stable predictions of coronary artery disease (CAD) than either approach can alone.

“The inclusion of polygenic risk in the ACC/AHA guidelines reflects a steady march toward clinical adoption of genomics-enabled tools that identify those who are ‘flying under the radar’ and could benefit from earlier intervention,” said Dr. Akash Kumar, co-founder of MyOme, in a statement. The convergence of new clinical guidance and validated technology may mark an inflection point, moving genetic risk assessment from a research concept to a clinical reality.

A More Complete Picture of Risk

For decades, doctors have relied on tools that assess risk based on observable factors like age, cholesterol levels, blood pressure, and smoking status. The latest of these is the PREVENT-ASCVD equation. While effective for large populations, these calculators can leave significant uncertainty for individual patients, particularly those who fall into a “borderline” or “intermediate” risk category.

This is where the new guidelines and polygenic risk scores (PRS) come into play. A PRS aggregates the effects of thousands, or even millions, of tiny genetic variants across a person's genome to produce a single score quantifying their inherited predisposition to a disease. Landmark studies have shown that individuals in the top percentiles of polygenic risk for coronary artery disease can face a risk level comparable to those with rare, single-gene mutations that cause familial hypercholesterolemia.

Under the new ACC/AHA framework, a high PRS can act as a tiebreaker for physicians and patients weighing decisions about starting cholesterol-lowering statin therapy or pursuing more aggressive lifestyle changes. It offers a biological glimpse into a patient's lifelong, inherent risk that isn't captured by a blood pressure reading or cholesterol panel, which can fluctuate over time.

MyOme’s research tackles a key challenge for the clinical utility of PRS: consistency. The study found that by integrating polygenic scores with established clinical predictors, their model provides a more stable and reliable risk estimate for an individual patient. This stability is crucial for clinical implementation, as doctors need to trust that a risk assessment won't dramatically change if a different but similar model is used.

“Polygenic risk captures inherited susceptibility to coronary artery disease that is not reflected in traditional clinical risk factors alone,” explained Dr. Akl Fahed, a cardiologist at Massachusetts General Hospital and an author on the MyOme study. “This study shows that integrating genetic and clinical risk factors can yield more consistent and reproducible risk estimates, supporting the potential role of combined models in preventive cardiology.”

A Cautious Welcome and Lingering Hurdles

While the cardiology community has largely welcomed the inclusion of PRS into the guidelines as a step forward, it comes with important caveats. In a notable detail, the guideline authors included PRS as a risk enhancer but did not assign it a formal Class of Recommendation or Level of Evidence. They acknowledged that while the science of risk prediction is strong, large-scale studies proving that the use of PRS directly leads to better patient outcomes—such as fewer heart attacks—are still needed.

“It’s a powerful new piece of information, but the key question remains: what is the most effective way to act on it?” commented one independent health economist not involved with the company or guidelines. “We need robust evidence to show that identifying someone with high polygenic risk and intervening earlier changes their trajectory in a cost-effective way.”

Another significant challenge facing the field is equity. The vast majority of genomic data used to develop and validate polygenic risk scores has been collected from individuals of European ancestry. This means the scores may be less accurate or reliable for people from other backgrounds, including those of African, Hispanic, or Asian descent, potentially widening existing health disparities.

“The danger is that we roll out a new technology that works best for one segment of the population,” noted a geneticist at a major academic medical center. “Ensuring these scores are validated and calibrated across diverse ancestries is not just a scientific goal; it’s an ethical imperative.” Companies in the space, including MyOme and its competitor Allelica, are actively working on multi-ancestry models to address this critical gap.

The Path from Lab to Widespread Clinical Use

The journey from a guideline mention to routine use in a primary care office is paved with regulatory and financial obstacles. Most polygenic risk scores are currently offered as Laboratory-Developed Tests (LDTs), a category that has historically operated under a less stringent regulatory framework than medical devices reviewed by the FDA. As the FDA looks to increase its oversight of LDTs, the regulatory pathway for these genetic tests remains a source of uncertainty for developers.

Even more critical is the question of reimbursement. For a test to be widely adopted, insurance companies must be willing to pay for it. Payers, including the Centers for Medicare & Medicaid Services (CMS), typically require strong evidence of clinical utility—proof that a test measurably improves health outcomes. The ACC/AHA's cautious endorsement, without definitive outcomes data, may give some payers pause.

For now, the recognition of polygenic risk in one of medicine’s most influential guidelines is a watershed moment. It provides a clear signal to clinicians that a patient’s DNA is a valid and valuable component of modern cardiovascular risk assessment. For patients, it opens the door to a future where a simple genetic test could provide a lifetime of insight, empowering them and their doctors to act decisively to protect their heart health long before the first symptom ever appears.